On Monday, Vaxcyte got an upgrade to its Relative Strength (RS) Rating, from 68 to 74.
This unique rating tracks market leadership by using a 1 (worst) to 99 (best) score that identifies how a stock's price performance over the last 52 weeks matched up against all other stocks.
Over 100 years of market history shows that the stocks that go on to make the biggest gains tend to have an RS Rating north of 80 in the early stages of their moves. See if Vaxcyte can continue to rebound and clear that threshold.
When To Sell Stocks To Lock In Profits And Minimize Losses
Vaxcyte has moved more than 5% past a 76.00 entry in a second-stage cup with handle, meaning it's now out of a proper buy range. Look for the stock to create a new chance to get in like a three-weeks tight or pullback to the 50-day or 10-week line.
The company posted 0% earnings growth in its most recent report. Sales gains came in at 0%.
Vaxcyte holds the No. 239 rank among its peers in the Medical-Biomed/Biotech industry group. ADMA Biologics, Corcept Therapeutics and Catalyst Pharmaceuticals are among the top 5 highly rated stocks within the group.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
IBD Stock Rating Upgrades: Rising Relative Strength
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
